Generally, azoospermia is characterized as obstructive (OA) or nonobstructive (NOA). Surgical
spermatozoa retrieval results vary in success rates. Proposing Intracytoplasmic Sperm
Injection (ICSI) to infertile couples with NOA depends on spermatogenesis, testicular
histology, and the ability to extract live spermatozoa from testis biopsy pieces.
Unfortunately, only 50% of testicular sperm extraction (TESE) results are positive (Zarezadeh
et al., 2021). Repeating sperm retrieval can cause TESE-induced hypoganadism, including
reduced testicular volume, erectile dysfunction, and testosterone deficiency (Eliveld et al.,
2018; Okada et al., 2002; Ozturk et al., 2011; Altinkilic et al., 2017; Akbal et al., 2017;
Binsaleh et al., 2017). The prognostic efficacy of hormonal, molecular, cytological, and
biochemical indicators for effective sperm recovery is limited (Corona et al., 2019).
Molecular, biochemical, clinical, and histopathological characteristics that identify NOA
males with advanced spermatogenesis foci up to the spermatozoon stage are crucial for
therapeutic purposes.
Recent research suggests that seminal protein expression patterns change dramatically between
azoospermic and fertile males (Zhang et al., 2021). TEX101 is a membrane protein only
produced by testicular germ cells and shed into seminal plasma (SP). Research suggests that
Tex101 malfunctions may impact male fertility (Jarvi et al., 2021). TEX101 is a germ cell
mono-specific marker present on sperm, round spermatids, and spermatocytes. At a threshold of
>5 ng/mL, TEX101 can distinguish NOA with Sertoli-cell only syndrome from other testis
histologies, such as hypospermatogenesis (67% specificity, 100% sensitivity) or maturation
arrest (54% sensitivity, 100% specificity) (Drabovich et al., 2013). ECM1, an epididymal
mono-specific marker, was below detection limits in males with OA semen but present in
detectable levels.
Research Template 3: Final Version: April 2019 NOA amounts in males. Clinical immunoassays of
ECM1 and TEX101 can predict sperm retrieval outcomes for assisted reproduction and lower the
cost of diagnosing azoospermia.
ELISA confirms that the lectin galactoside-binding, soluble 3 binding protein (LGALS3BP) is
expressed throughout the male genital tract. Its physiological role in cell-to-cell
interaction through extracellular matrix suggests a possible role in spermatogenesis,
particularly in the late stage, despite not being a germ-cell specific marker (Cannarella et
al., 2020). Patients with a good result of TESE had significantly greater levels of LGALS3BP
in the SP. A cut-off of 153 ng/mL was observed with 100% sensitivity and 45% specificity.
Freour et al. (2013) identified a key issue in their analysis due to the small number of
instances (n=40) with lower AUC values. Araujo and Bertolla (2021) propose that LGALS3BP may
predict TESE success in NOA patients before ICSI.